These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 22593496)
1. Multiple myeloma: myeloablative therapy with autologous stem cell support versus chemotherapy: a meta-analysis. Faussner F; Dempke WC Anticancer Res; 2012 May; 32(5):2103-9. PubMed ID: 22593496 [TBL] [Abstract][Full Text] [Related]
2. Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis. Dhakal B; Szabo A; Chhabra S; Hamadani M; D'Souza A; Usmani SZ; Sieracki R; Gyawali B; Jackson JL; Asimakopoulos F; Hari PN JAMA Oncol; 2018 Mar; 4(3):343-350. PubMed ID: 29302684 [TBL] [Abstract][Full Text] [Related]
3. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials. Koreth J; Cutler CS; Djulbegovic B; Behl R; Schlossman RL; Munshi NC; Richardson PG; Anderson KC; Soiffer RJ; Alyea EP Biol Blood Marrow Transplant; 2007 Feb; 13(2):183-96. PubMed ID: 17241924 [TBL] [Abstract][Full Text] [Related]
4. Novel agents-based regimens as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials. Wang L; Ran X; Wang B; Sheng Z; Liu L Hematol Oncol; 2012 Jun; 30(2):57-61. PubMed ID: 21809367 [TBL] [Abstract][Full Text] [Related]
5. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults. Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N Cochrane Database Syst Rev; 2012 Jan; 1(1):CD007678. PubMed ID: 22258971 [TBL] [Abstract][Full Text] [Related]
6. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. Barlogie B; Kyle RA; Anderson KC; Greipp PR; Lazarus HM; Hurd DD; McCoy J; Moore DF; Dakhil SR; Lanier KS; Chapman RA; Cromer JN; Salmon SE; Durie B; Crowley JC J Clin Oncol; 2006 Feb; 24(6):929-36. PubMed ID: 16432076 [TBL] [Abstract][Full Text] [Related]
7. Impact of autologous transplantation on survival in patients with newly diagnosed multiple myeloma who have high-risk cytogenetics: A meta-analysis of randomized controlled trials. Chakraborty R; Siddiqi R; Willson G; Gupta S; Asghar N; Husnain M; Aljama MA; Behera TR; Anwer F; Perrot A; Riaz IB Cancer; 2022 Jun; 128(12):2288-2297. PubMed ID: 35377484 [TBL] [Abstract][Full Text] [Related]
8. ThaDD plus high dose therapy and autologous stem cell transplantation does not appear superior to ThaDD plus maintenance in elderly patients with de novo multiple myeloma. Offidani M; Leoni P; Corvatta L; Polloni C; Gentili S; Savini A; Alesiani F; Brunori M; Catarini M; Visani G; Samori A; Burattini M; Centurioni R; Montanari M; Fraticelli P; Ruggieri M; Falcioni S; Galieni P Eur J Haematol; 2010 Jun; 84(6):474-83. PubMed ID: 20331733 [TBL] [Abstract][Full Text] [Related]
9. The role of autologous hematopoietic stem cell transplantation in multiple myeloma. Harousseau JL; Attal M Semin Hematol; 1997 Jan; 34(1 Suppl 1):61-6. PubMed ID: 9122747 [TBL] [Abstract][Full Text] [Related]
10. Randomized trial of single compared with tandem high-dose chemotherapy followed by autologous stem-cell transplantation in patients with chemotherapy-sensitive metastatic breast cancer. Kröger N; Frick M; Gluz O; Mohrmann S; Metzner B; Jackisch C; Ko Y; Lindemann HW; Meier CR; Lohrmann HP; Ruffert U; Hänel M; Bodenstein H; Neubauer A; Ehninger G; Wolf HH; Kolbe K; Burock K; Zander AR; Nitz U J Clin Oncol; 2006 Aug; 24(24):3919-26. PubMed ID: 16921043 [TBL] [Abstract][Full Text] [Related]
11. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation. Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH; Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634 [TBL] [Abstract][Full Text] [Related]
12. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. Spencer A; Prince HM; Roberts AW; Prosser IW; Bradstock KF; Coyle L; Gill DS; Horvath N; Reynolds J; Kennedy N J Clin Oncol; 2009 Apr; 27(11):1788-93. PubMed ID: 19273705 [TBL] [Abstract][Full Text] [Related]
13. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival. Palumbo A; Attal M; Roussel M Clin Cancer Res; 2011 Mar; 17(6):1253-63. PubMed ID: 21411441 [TBL] [Abstract][Full Text] [Related]
14. Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma. Cavo M; Di Raimondo F; Zamagni E; Patriarca F; Tacchetti P; Casulli AF; Volpe S; Perrone G; Ledda A; Ceccolini M; Califano C; Bigazzi C; Offidani M; Stefani P; Ballerini F; Fiacchini M; de Vivo A; Brioli A; Tosi P; Baccarani M J Clin Oncol; 2009 Oct; 27(30):5001-7. PubMed ID: 19720903 [TBL] [Abstract][Full Text] [Related]
15. Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response. Mina R; Petrucci MT; Corradini P; Spada S; Patriarca F; Cerrato C; De Paoli L; Pescosta N; Ria R; Malfitano A; Musto P; Baldini L; Guglielmelli T; Gamberi B; Mannina D; Benevolo G; Zambello R; Falcone AP; Palumbo A; Nagler A; Calafiore V; Hájek R; Spencer A; Boccadoro M; Bringhen S Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):533-540. PubMed ID: 29910180 [TBL] [Abstract][Full Text] [Related]
17. The role of autologous stem cell transplantation in the management of multiple myeloma. Fermand JP; Brechignac S Pathol Biol (Paris); 1999 Feb; 47(2):199-202. PubMed ID: 10192889 [TBL] [Abstract][Full Text] [Related]
18. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. Fermand JP; Katsahian S; Divine M; Leblond V; Dreyfus F; Macro M; Arnulf B; Royer B; Mariette X; Pertuiset E; Belanger C; Janvier M; Chevret S; Brouet JC; Ravaud P; J Clin Oncol; 2005 Dec; 23(36):9227-33. PubMed ID: 16275936 [TBL] [Abstract][Full Text] [Related]
19. Feasibility and outcome of tandem stem cell autotransplants in multiple myeloma. Galli M; Nicolucci A; Valentini M; Belfiglio M; Delaini F; Crippa C; Barbui AM; Giussani U; Rambaldi A; Barbui T Haematologica; 2005 Dec; 90(12):1643-9. PubMed ID: 16330437 [TBL] [Abstract][Full Text] [Related]
20. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. Child JA; Morgan GJ; Davies FE; Owen RG; Bell SE; Hawkins K; Brown J; Drayson MT; Selby PJ; N Engl J Med; 2003 May; 348(19):1875-83. PubMed ID: 12736280 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]